These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21631134)

  • 1. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
    Schättler H; Ledzewicz U; Cardwell B
    Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
    Ledzewicz U; Maurer H; Schättler H
    Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.
    Ledzewicz U; Schättler H
    J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment.
    Ledzewicz U; Marriott J; Maurer H; Schättler H
    Math Med Biol; 2010 Jun; 27(2):157-79. PubMed ID: 20513667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of vascular-targeting drugs in a computational model of tumor growth.
    Gevertz J
    Phys Rev E Stat Nonlin Soft Matter Phys; 2012 Apr; 85(4 Pt 1):041914. PubMed ID: 22680505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.
    D'Onofrio A; Gandolfi A
    Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal scheduling of radiotherapy and angiogenic inhibitors.
    Ergun A; Camphausen K; Wein LM
    Bull Math Biol; 2003 May; 65(3):407-24. PubMed ID: 12749532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
    d'Onofrio A; Gandolfi A
    Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.
    Sinek J; Frieboes H; Zheng X; Cristini V
    Biomed Microdevices; 2004 Dec; 6(4):297-309. PubMed ID: 15548877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cells proliferation and migration under the influence of their microenvironment.
    Friedman A; Kim Y
    Math Biosci Eng; 2011 Apr; 8(2):371-83. PubMed ID: 21631135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On optimal delivery of combination therapy for tumors.
    d'Onofrio A; Ledzewicz U; Maurer H; Schättler H
    Math Biosci; 2009 Nov; 222(1):13-26. PubMed ID: 19706298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.
    Yonucu S; Yιlmaz D; Phipps C; Unlu MB; Kohandel M
    PLoS Comput Biol; 2017 Sep; 13(9):e1005724. PubMed ID: 28922358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical modeling of cyclic treatments of chronic myeloid leukemia.
    Komarova NL
    Math Biosci Eng; 2011 Apr; 8(2):289-306. PubMed ID: 21631131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method.
    Kassara K; Moustafid A
    Math Biosci; 2011 Jun; 231(2):135-43. PubMed ID: 21377480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug scheduling of cancer chemotherapy based on natural actor-critic approach.
    Ahn I; Park J
    Biosystems; 2011 Nov; 106(2-3):121-9. PubMed ID: 21839140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies.
    McDougall SR; Anderson AR; Chaplain MA; Sherratt JA
    Bull Math Biol; 2002 Jul; 64(4):673-702. PubMed ID: 12216417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer.
    Bunimovich-Mendrazitsky S; Goltser Y
    Math Biosci Eng; 2011 Apr; 8(2):529-47. PubMed ID: 21631144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells.
    Bertolini F
    Cancer Metastasis Rev; 2008 Mar; 27(1):95-101. PubMed ID: 18066648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.